<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03201419</url>
  </required_header>
  <id_info>
    <org_study_id>000233</org_study_id>
    <secondary_id>2016-003851-31</secondary_id>
    <nct_id>NCT03201419</nct_id>
  </id_info>
  <brief_title>A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults</brief_title>
  <acronym>DAWN</acronym>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to investigate the efficacy, safety and tolerability of
      different oral doses of FE 201836, with desmopressin as a benchmark, during 12 weeks of
      treatment for nocturia due to nocturnal polyuria in adults
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 27, 2017</start_date>
  <completion_date type="Anticipated">October 25, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 25, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Following randomisation, the first 125 subjects will be treated daily with placebo, FE 201836 or desmopressin for up to 12 weeks. Subjects may hereafter be randomised to one of 8 treatment groups for 12 weeks: placebo, 6 different doses of FE 201836, or desmopressin</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Each subject will receive 2 medications (an oral solution and an orally disintegrating tablet (ODT) formulation) throughout the trial, in order to keep the treatment blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in number of nocturnal voids</measure>
    <time_frame>during 12 weeks of treatment</time_frame>
    <description>Nocturnal voids are defined as voids occuring from 5 minutes after bedtime until rising in the morning</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in number of nocturnal voids</measure>
    <time_frame>Week 1, 4, 8 and 12</time_frame>
    <description>Nocturnal voids are defined as voids occuring from 5 minutes after bedtime until rising in the morning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder rate in nocturnal voids</measure>
    <time_frame>Week 1, 4, 8 and 12 and during 12 weeks of treatment</time_frame>
    <description>Defined as 50% reduction in nocturnal voids from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Nocturia Impact (NI) Diary Total Score</measure>
    <time_frame>Week 1, 4, 8 and 12 and during 12 weeks of treatment</time_frame>
    <description>Assessed by scores from 0-4 of 11 core items</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in NI Diary Overall Impact Score</measure>
    <time_frame>Week 1, 4, 8 and 12 and during 12 weeks of treatment</time_frame>
    <description>Assessed by 1 overall Quality of Life (QoL) question</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Improvement (PGI-I) urinary symptoms scores</measure>
    <time_frame>Week 1, 4, 8 and 12</time_frame>
    <description>Assessed by a patient questionnaire (summary of change in nocturia coded from 1-7)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Patient Global Impression of Severity (PGI-S) scores</measure>
    <time_frame>Week 1, 4, 8 and 12</time_frame>
    <description>Assessed by a patient questionnaire (summary of severity of nocturia symptoms coded from 1-4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Bother</measure>
    <time_frame>Week 1, 4, 8 and 12</time_frame>
    <description>Assessed by the Hsu 5-point Likert Bother scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Insomnia Severity Index (ISI)</measure>
    <time_frame>Week 4, 8 and 12</time_frame>
    <description>Assessed by a patient questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in First Undisturbed Sleep Period (FUSP)</measure>
    <time_frame>Week 1, 4, 8 and 12 and during 12 weeks of treatment</time_frame>
    <description>FUSP is defined as the time in minutes from the time of going to bed to the time of first nocturnal void, or time of awakening if no void occured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in nocturnal diuresis rate (hourly) profiles</measure>
    <time_frame>Week 1 and 12</time_frame>
    <description>The nocturnal diuresis rate (mL/min) is calculated from the mean of 3 days Nocturnal Urine Volume (NUV) and total time in bed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in NUV</measure>
    <time_frame>Week 1 and 12</time_frame>
    <description>NUV is defined as the total urine volume from 5 minutes after bedtime with the intention to sleep until the first void within 30 minutes of rising in the morning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nights with at most one nocturnal void</measure>
    <time_frame>During 12 weeks of treatment</time_frame>
    <description>Calculated as percentage of nights during the treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nights with no nocturnal voids</measure>
    <time_frame>During 12 weeks of treatment</time_frame>
    <description>Calculated as percentage of nights during the treatment period</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Nocturia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Desmopressin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Desmopressin ODT (25 μg for females and 50 μg for males)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FE 201836 (1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FE 201836 (2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FE 201836 (3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FE 201836 (4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FE 201836 (5)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FE 201836 (6)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 6</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FE 201836</intervention_name>
    <description>Oral solution for daily intake</description>
    <arm_group_label>FE 201836 (1)</arm_group_label>
    <arm_group_label>FE 201836 (2)</arm_group_label>
    <arm_group_label>FE 201836 (3)</arm_group_label>
    <arm_group_label>FE 201836 (4)</arm_group_label>
    <arm_group_label>FE 201836 (5)</arm_group_label>
    <arm_group_label>FE 201836 (6)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desmopressin</intervention_name>
    <description>Desmopressin Orally Disintegrating Tablet (ODT)</description>
    <arm_group_label>Desmopressin</arm_group_label>
    <other_name>NOCDURNA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral solution</intervention_name>
    <description>Manufactured to mimic experimental drug</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Desmopressin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo ODT</intervention_name>
    <description>Manufactured to mimic active comparator drug</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>FE 201836 (1)</arm_group_label>
    <arm_group_label>FE 201836 (2)</arm_group_label>
    <arm_group_label>FE 201836 (3)</arm_group_label>
    <arm_group_label>FE 201836 (4)</arm_group_label>
    <arm_group_label>FE 201836 (5)</arm_group_label>
    <arm_group_label>FE 201836 (6)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults ≥18 years of age (at the time of written consent)

          -  Medical history of, or subject reported nocturia symptoms during the 6 months prior to
             Visit 1

          -  ≥2 nocturnal voids (an average over 3 days) as documented in the 3-day e-Diary prior
             to Visit 2

          -  The largest single voided volume must be &gt;250 mL (at least 1 void &gt;250 mL) as
             documented in the 3-day e-Diary prior to Visit 2

          -  Nocturnal polyuria, defined as Nocturnal Polyuria index &gt;33%, a ratio of Nocturnal
             Urine Volume in excess of 33% of total daily (24-hour) urine volume as documented in
             the 3-day e-Diary prior to Visit 2

          -  Bothered by nocturia as defined by an Nocturia Impact Diary Total Score of ≥10 points
             (raw score) as documented in the 3-day e-Diary prior to Visit 2

          -  ≥20% decrease in the nocturnal diuresis rate (mL/min) (that was recorded at Visit 2)
             as documented in the 3-day e-Diary prior to Visit 3

        Exclusion Criteria:

          -  Current diagnosis of Obstructive Sleep Apnoea (OSA). In case of no current diagnosis
             of Obstructive Sleep Apnoea, high-risk subjects should be excluded as assessed by the
             STOP-Bang questionnaire at Visit 1

          -  Restless Legs Syndrome (RLS)

          -  History or suspicion of moderate to severe LUTS with or without BOO. In case of
             suspicion of moderate or severe LUTS with or without BOO, subjects should be excluded
             from the trial as follows:

               -  Female subjects with a Post-void Residual (PVR) &gt;150 mL, as confirmed by
                  ultrasound during screening prior to Visit 2

               -  Male subjects with a PVR &gt;150 mL, as confirmed by ultrasound during screening
                  prior to Visit 2, and who also have International Prostate Symptom Score (IPSS)
                  ≥8 points and urinary flow &lt;5 mL/s, as confirmed by uroflowmetry during screening
                  prior to Visit 2

          -  Urinary incontinence defined as an average of &gt;1 episode/day in the 3-day e-Diary
             prior to Visit 2 (occasional urge incontinence during daytime or at night on the way
             to void is not necessarily exclusionary)

          -  Predominant daytime voiding dysfunction due to Overactive Bladder, at Visit 2, defined
             as:

               -  Frequency (an average of &gt;8 daytime voids per day during the 3-day diary period)
                  and

               -  ≥1 daily urgency episode (the subject could not postpone voiding or the subject
                  leaked before arriving to the toilet)

          -  Any pelvic or lower urinary tract surgery and/or radio therapy or previous pelvic
             irradiation within the past 6 months prior to Visit 1. Including e.g., transurethral
             resection for Bladder Outlet Obstruction or Benign Prostatic Hyperplasia, hysterectomy
             or female incontinence procedures

          -  Genito-urinary tract pathology that can in the investigator's opinion be responsible
             for urgency or urinary incontinence e.g., symptomatic or recurrent urinary tract
             infections, interstitial cystitis, bladder-related pain, chronic pelvic pain syndrome,
             or stone in the bladder or urethra causing symptoms

          -  A history of cancer with the last date of disease activity/presence of malignancy
             within the last 12 months prior to Visit 1, except for adequately treated basal cell
             carcinoma of the skin

          -  History of any neurological disease affecting bladder function or muscle strength
             (e.g., Multiple Sclerosis, Parkinson's, spinal cord injury, spina bifida)

          -  Habitual (fluid intake &gt;3L per day) or psychogenic polydipsia

          -  Uncontrolled hypertension, as judged by the investigator

          -  Uncontrolled diabetes mellitus, as judged by the investigator

          -  Central or nephrogenic diabetes insipidus

          -  Known history of Syndrome of Inappropriate Antidiuretic Hormone (SIADH) secretion

          -  History of gastric retention

          -  Suspicion or evidence of congestive heart failure, (New York Heart Association (NYHA)
             class II, III, IV)

          -  Hyponatraemia:

               -  Serum sodium level &lt;135 mmol/L at Visit 1(re-tested, with results available
                  within 7 days)

               -  Serum sodium level &lt;130 mmol/L at Visit 3 (re-tested, with results available
                  within 7 days)

          -  Use of any prohibited therapy listed below:

               -  Current or former (within 3 months prior to screening) treatment with any other
                  investigational medicinal product (IMP)

               -  Unstable electrostimulation or behavioural bladder training program less than 3
                  months prior to screening (stable electrostimulation or behavioural bladder
                  training program started at least 3 months before screening are acceptable)

               -  Thiazide diuretics

               -  Antiarrhythmic agents

               -  V2-receptor antagonists/agonists (e.g., vaptans/desmopressin, vasopressin)

               -  Loperamide

               -  Botulinum toxin (cosmetic non-urological use is acceptable)

               -  Valproate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Development Support</last_name>
    <phone>+1 833-548-1402 (US/Canada)</phone>
    <email>DK0-Disclosure@ferring.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Clinical Development Support</last_name>
    <phone>+1 862-286-5200 (outside US)</phone>
    <email>DK0-Disclosure@ferring.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tri Valley Urology Medical Group</name>
      <address>
        <city>Murrieta</city>
        <state>California</state>
        <zip>92562</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>San Diego Clinical Trials</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Downtown Women's Health Care</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Genitourinary Surgical Consultants, P.C.</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Florida Medical Research</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Women's Medical Research Group, LLC</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33759</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research of South Florida</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pharmax Research Clinic</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Florida</name>
      <address>
        <city>Pompano Beach</city>
        <state>Florida</state>
        <zip>33060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meridien Research, Inc.</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33709</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>American Health Network of Indiana, LLC</name>
      <address>
        <city>Avon</city>
        <state>Indiana</state>
        <zip>46123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>American Health Network of Indiana, LLC</name>
      <address>
        <city>Greenfield</city>
        <state>Indiana</state>
        <zip>46140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bay State Clinical Trials, Inc.</name>
      <address>
        <city>Watertown</city>
        <state>Massachusetts</state>
        <zip>02472</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beyer Research</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Quality Clinical Research Center, Inc.</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Urology Center Research Institute, LLC</name>
      <address>
        <city>Englewood</city>
        <state>New Jersey</state>
        <zip>07631</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Premier Medical Group of the Hudson Valley, PC</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Carolina Clinical Trials, LLC</name>
      <address>
        <city>Concord</city>
        <state>North Carolina</state>
        <zip>28025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>PMG Research of Raleigh, LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>PMG Research of Wilmington, LLC</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>HWC Women's Research Center</name>
      <address>
        <city>Englewood</city>
        <state>Ohio</state>
        <zip>45322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>PMG Research of Charleston, LLC</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MCA Research - Partner</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77079</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ericksen Research &amp; Development, LLC</name>
      <address>
        <city>Clinton</city>
        <state>Utah</state>
        <zip>84015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Research Institute</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ULB Hopital Erasme</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge - Campus Vercruysselaan</name>
      <address>
        <city>Kortrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>DIEX Recherche Quebec Inc.</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique Médicale St-Louis (Recherche) inc d/b/a/ Centre de Recherche Saint-Louis</name>
      <address>
        <city>Québec</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bluewater Health-Norman Site</name>
      <address>
        <city>Sarnia</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHUS - Hôpital Fleurimont</name>
      <address>
        <city>Sherbrooke</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>DIEX Recherche Sherbrooke Inc.</name>
      <address>
        <city>Sherbrooke</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. Anil K. Gupta Medicine Professional Corporation</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Brno, Dept of Klinika nemoci plicnich a tuberkulozy</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Krajska nemocnice Liberec, a.s.</name>
      <address>
        <city>Liberec</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Urocentrum Plzen</name>
      <address>
        <city>Plzen</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Thomayerova nemocnice, PARENT</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Krajska zdravotni, a.s. - Masarykova nemocnice v Usti nad Labem, o.z., Dept of Oddeleni urologie a roboticke chirurgie</name>
      <address>
        <city>Ústí Nad Labem</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis fuer Urologie und Andrologie</name>
      <address>
        <city>Duisburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Urologische Gemeinschaftspraxis</name>
      <address>
        <city>Emmendingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Weiden, Klinik f. Urologie, Andrologie und Kinderurologie</name>
      <address>
        <city>Weiden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jahn Ferenc Del-pesti Korhaz es Rendelointezet</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Synexus Magyarorszag Kft.</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bagoly Egeszseghaz</name>
      <address>
        <city>Kecskemet</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SzSzB Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz Urologia</name>
      <address>
        <city>Nyiregyhaza</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont, Urologiai Klinika</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet</name>
      <address>
        <city>Szolnok</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nasz Lekarz Osrodek Badan Klinicznych</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2017</study_first_submitted>
  <study_first_submitted_qc>June 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2017</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nocturia</mesh_term>
    <mesh_term>Polyuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deamino Arginine Vasopressin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

